Fibromyalgia (Fibromyalgia Syndrome) – Global Clinical Trials Review, H2, 2021

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: December 13, 2021 Report Code: GDHC6817CTIDB-ST

Select Item

GlobalData’s clinical trial report provides an overview of the fibromyalgia (Fibromyalgia Syndrome) clinical trials scenario. This report provides top-line data relating to the clinical trials on fibromyalgia (Fibromyalgia Syndrome). The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials (based on several ongoing trials). GlobalData clinical trial reports are generated using GlobalData’s proprietary Pharma clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news, etc across the globe. Clinical trials database undergoes periodic updates by dynamic process.

Fibromyalgia (Fibromyalgia Syndrome) clinical trial report consists of 558 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, Phase I, and Phase 0 stand at 41, 70, 82, 189, and 2 respectively. Similarly, the trials with different status compile of completed – 404, ongoing – 48, planned – 43, suspended – 3, terminated – 26, and withdrawn – 34. Out of 404 completed trials 241 trials have achieved endpoint.

What are the market dynamics of the global fibromyalgia (Fibromyalgia Syndrome) therapeutics clinical trials sector?

The number of fibromyalgia (fibromyalgia syndrome) clinical trials conducted globally, has increased by over 19% for the period 2016- 2020. As of December 2021, out of 404 completed trials, 294 trials have results and 241 trials reached endpoints. During the same period, there were 197 clinical trials in Phase I, of which 7 clinical trials were in progress for the time period of 1995-2021, and 48 clinical trials in progress of which 24 trials were in Phase II study. The trials that were terminated/suspended or withdrawn accounted for 63. This was due to the lack of efficacy, safety, and lack of accrual of subjects.

What are the top regions and countries in the global fibromyalgia (Fibromyalgia Syndrome) therapeutics clinical trials sector?

In total there were 558 clinical trials conducted on fibromyalgia (fibromyalgia syndrome), as of December 2021, of these 190 clinical trials were in North America. During the same period, the US has the highest average patient enrollment in fibromyalgia (Fibromyalgia Syndrome) clinical trials.

North America: The US has the highest number of fibromyalgia (fibromyalgia syndrome) clinical trials followed by Canada and Mexico.

Europe: Among the European countries, Spain has the highest number of fibromyalgia (fibromyalgia syndrome) clinical trials followed by France, Italy, the UK, and Germany.

Asia-Pacific: In the Asia-Pacific region, China has the highest number of fibromyalgia (fibromyalgia syndrome) clinical trials followed by Thailand, South Korea, India, and Japan.

Middle East and Africa: Iran has the highest number of fibromyalgia (fibromyalgia syndrome) clinical trials followed by Israel and South Africa and Egypt.

South and Central America: Brazil has the highest number of fibromyalgia (fibromyalgia syndrome) clinical trials followed by Chile, Argentina, Venezuela, and Colombia.

G7 countries: Among the G7 (The US, the UK Germany, France, Italy, Canada, and Japan) countries, Canada has the highest proportion of fibromyalgia (Fibromyalgia Syndrome) to central nervous system clinical trials as of December 2021. In total there were 301 clinical trials conducted on fibromyalgia (Fibromyalgia Syndrome), in G7 countries, of these 162 clinical trials were in the US. During the same period, there were 23 clinical trials in progress and 185 trials are completed. The trials that are terminated/suspended or withdrawn accounted for 32.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Indonesia has the highest proportion of fibromyalgia (Fibromyalgia Syndrome) to central nervous system clinical trials as of December 2021. In total there were 98 clinical trials conducted on fibromyalgia (Fibromyalgia Syndrome), in E7 countries, of these 32 clinical trials were in China.

Global fibromyalgia (Fibromyalgia Syndrome) therapeutics clinical trials sector, by regions

Global fibromyalgia (Fibromyalgia Syndrome) therapeutics clinical trials sector, by regions

For more regional insights, download a free report sample

Which are the key companies in the global fibromyalgia (Fibromyalgia Syndrome) therapeutics clinical trials sector?

As of December 2021, Eli Lilly and Co. sponsored the highest number of fibromyalgia (fibromyalgia syndrome) clinical trials followed by Viatris Inc and Pfizer Inc. Other major companies in the sector are Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Co Ltd, Tonix Pharmaceuticals Holding Corp, Syneos Health Inc, UCB SA, Dr. Reddy’s Laboratories Ltd, and C. H. Boehringer Sohn AG & Co KG.

Global fibromyalgia (Fibromyalgia Syndrome) therapeutics clinical trials sector, by key companies

Global fibromyalgia (Fibromyalgia Syndrome) therapeutics clinical trials sector, by key companies

To know more about key companies, download a free report sample

Market report scope

Key countries The US, the UK, Spain, Canada, China, Germany, Japan, France, Italy, and Belgium
Key companies Eli Lilly and Co, Viatris Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd, Daiichi Sankyo Co Ltd, Tonix Pharmaceuticals Holding Corp, Syneos Health Inc, UCB SA, Dr. Reddy’s Laboratories Ltd, and C. H. Boehringer Sohn AG & Co KG.

Scope

  • The report provides a snapshot of the global clinical trials landscape.
  • Report provides top-level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status.
  • The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
  • The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for unaccomplishment.
  • The Report provides enrollment trends for the past five years.
  • Report provides the latest news for the past three months.

Reasons to Buy

  • Assists in formulating key business strategies with regard to investment.

  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost.

  • Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.

  • Supports understanding of trials count and enrollment trends by country in the global therapeutics market.

  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.

  • Facilitates clinical trial assessment of the indication on a global, regional, and country-level.

Table of Contents

Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Fibromyalgia (Fibromyalgia Syndrome) to Central Nervous System Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Fibromyalgia (Fibromyalgia Syndrome) to Central Nervous System Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials

Prominent Drugs

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Source

Table

List of Tables

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials by Region, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, North America, Top Countries, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2021*

Proportion of Fibromyalgia (Fibromyalgia Syndrome) to Central Nervous System Clinical Trials, G7 Countries (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*

Proportion of Fibromyalgia (Fibromyalgia Syndrome) to Central Nervous System Clinical Trials, E7 Countries (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials by Phase, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*

Figures

List of Figures

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials by Region (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, North America, Top Countries (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2021*

Proportion of Fibromyalgia (Fibromyalgia Syndrome) to Central Nervous System Clinical Trials, G7 Countries (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, G7 Countries, Clinical Trials by Phase, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2021*

Proportion of Fibromyalgia (Fibromyalgia Syndrome) to Central Nervous System Clinical Trials, E7 Countries (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, E7 Countries, Clinical Trials by Phase, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials by Phase (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials In Progress by Phase, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics, Global, Clinical Trials by Trial Status, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, by End Point Status, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2016-2020

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, Key Sponsors, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2021*

Fibromyalgia (Fibromyalgia Syndrome) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2021*

GlobalData Methodology

Frequently asked questions

Fibromyalgia (Fibromyalgia Syndrome) – Global Clinical Trials Review, H2, 2021 standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Pharmaceuticals
New
Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…
$6,995 | March 2024
Pharmaceuticals
New
Clinical Trials Scorecard for Investigations in 2023
$695 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Fibromyalgia (Fibromyalgia Syndrome) – Global Clinical Trials Review, H2, 2021 in real time.

  • Access a live Fibromyalgia (Fibromyalgia Syndrome) – Global Clinical Trials Review, H2, 2021 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more